Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.

A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.

Cancer care demand is constantly shifting, with panelists at PCOC 2026 debating the benefits of automation vs retaining live patient access.